Bone Metastasis – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Bone Metastasis – Pipeline Review, H1 2020’, provides an overview of the Bone Metastasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Bone Metastasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Metastasis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Bone Metastasis

– The report reviews pipeline therapeutics for Bone Metastasis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Bone Metastasis therapeutics and enlists all their major and minor projects

– The report assesses Bone Metastasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Bone Metastasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Bone Metastasis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Bone Metastasis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Ablynx NV

Altum Pharmaceuticals Inc

Amgen Inc

Bayer AG

BiologicsMD Inc

BioNTech SE

CSPC Pharmaceutical Group Ltd

Deciphera Pharmaceuticals Inc

Eli Lilly and Co

Genor BioPharma Co Ltd

Hengenix Biotech Inc

ITM Isotopen Technologien Munchen AG

Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd

Jiangsu T-mab BioPharma Co Ltd

Livzon MabPharm Inc

Lupin Ltd

Luye Pharma Group Ltd

MetCure Therapeutics LLC

Mirati Therapeutics Inc

NeuClone Pty Ltd

Oncolix Inc

Orion Biotechnology Canada Ltd

Qilu Pharmaceutical Co Ltd

R Pharm

Reliance Life Sciences Pvt Ltd

Serene LLC

Sonnet BioTherapeutics Inc

Terpenoid Therapeutics Inc

Zhejiang Hisun Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Introduction

Bone Metastasis - Overview

Bone Metastasis - Therapeutics Development

Bone Metastasis - Therapeutics Assessment

Bone Metastasis - Companies Involved in Therapeutics Development

Bone Metastasis - Drug Profiles

Bone Metastasis - Dormant Projects

Bone Metastasis - Discontinued Products

Bone Metastasis - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Bone Metastasis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Bone Metastasis – Pipeline by Ablynx NV, H1 2020

Bone Metastasis – Pipeline by Altum Pharmaceuticals Inc, H1 2020

Bone Metastasis – Pipeline by Amgen Inc, H1 2020

Bone Metastasis – Pipeline by Bayer AG, H1 2020

Bone Metastasis – Pipeline by BiologicsMD Inc, H1 2020

Bone Metastasis – Pipeline by BioNTech SE, H1 2020

Bone Metastasis – Pipeline by CSPC Pharmaceutical Group Ltd, H1 2020

Bone Metastasis – Pipeline by Deciphera Pharmaceuticals Inc, H1 2020

Bone Metastasis – Pipeline by Eli Lilly and Co, H1 2020

Bone Metastasis – Pipeline by Genor BioPharma Co Ltd, H1 2020

Bone Metastasis – Pipeline by Hengenix Biotech Inc, H1 2020

Bone Metastasis – Pipeline by ITM Isotopen Technologien Munchen AG, H1 2020

Bone Metastasis – Pipeline by Jiangsu Rhentai Pharmaceutical Biotechnology Co Ltd, H1 2020

Bone Metastasis – Pipeline by Jiangsu T-mab BioPharma Co Ltd, H1 2020

Bone Metastasis – Pipeline by Livzon MabPharm Inc, H1 2020

Bone Metastasis – Pipeline by Lupin Ltd, H1 2020

Bone Metastasis – Pipeline by Luye Pharma Group Ltd, H1 2020

Bone Metastasis – Pipeline by MetCure Therapeutics LLC, H1 2020

Bone Metastasis – Pipeline by Mirati Therapeutics Inc, H1 2020

Bone Metastasis – Pipeline by NeuClone Pty Ltd, H1 2020

Bone Metastasis – Pipeline by Oncolix Inc, H1 2020

Bone Metastasis – Pipeline by Orion Biotechnology Canada Ltd, H1 2020

Bone Metastasis – Pipeline by Qilu Pharmaceutical Co Ltd, H1 2020

Bone Metastasis – Pipeline by R Pharm, H1 2020

Bone Metastasis – Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020

Bone Metastasis – Pipeline by Serene LLC, H1 2020

Bone Metastasis – Pipeline by Sonnet BioTherapeutics Inc, H1 2020

Bone Metastasis – Pipeline by Terpenoid Therapeutics Inc, H1 2020

Bone Metastasis – Pipeline by Zhejiang Hisun Pharmaceutical Co Ltd, H1 2020

Bone Metastasis – Dormant Projects, H1 2020

Bone Metastasis – Dormant Projects, H1 2020 (Contd..1), H1 2020

Bone Metastasis – Dormant Projects, H1 2020 (Contd..2), H1 2020

Bone Metastasis – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Bone Metastasis, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Routes of Administration, H1 2020

Number of Products by Stage and Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports